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57%, respectively. RT-CHT was superior to RT alone in terms of OS (p<0.001) and LPFS (p<0.001), but not the DMFS. In analysis 3
(n=146), MST and 5-yr OS, LPFS and the DMFS rates were 17 months, 20 months and 20 months, respectively and 15%, 26% and
33%, respectively. RT-CHT was superior to RT alone in terms of OS (p=0.003) and LPFS (p=0.06), but not the DMFS (p=0.43). Acute
and late high-grade toxicity in all three analyses was low. In all three analyses, only age did not inﬂuence any of endpoints. In
analysis 1, treatment did not inﬂuence DMFS, histology being of borderline signiﬁcance. In analysis 3, CHT did not inﬂuence LPFS
and DMFS.
Conclusion. Hfx RT-CHT achieved excellent results with low toxicity and identiﬁed independent prognostic factors inﬂuencing
outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.763
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Purpose. To evaluate the outcome of patients (pts) with non-small cell lung cancer (NSCLC) PET-CT staged treated at different
dose levels according to a individualised prescription based on lung doses restrictions criteria.
Method. We analyse 46 consecutive NSCLC pts, staged I–III, treated with radiotherapy with/without chemotherapy. Nodal regions
were included only if determined on PET-CT to be disease involved. Dose prescription was as high as possible (60, 66, 70 and 74
Gy, 2 Gy/fx) provided not exceeding Mean Lung Dose 16.5 Gy and/or V20≤35%. 12 pts were treated up to 60 Gy, 13 up to 66 Gy, 13
up to 70 Gy and 8 up to 74 Gy. Pts were analysed in follow-up for overall survival (OS) disease-free survival (DFS), local regional
recurrence (LCR) in-ﬁeld failure (IFF) out-ﬁeld failure (OFF) and distant metastases (DM).
Results. The median follow-up was 17.9 (3.8–49.2) in months (m) the mean actuarial OS was 29.2, OS 1-year (y) and 2-y actuarial
survival were 68% and 54%, respectively. The mean actuarial DFS was 18.4, DFS 1-y and 2-y actuarial survival were 46% and 26%,
respectively. There were 29 LCR (28 IFF, 1 OFF). 6 developed DM. Log Rank (LR) test across dose level was signiﬁcant for DFS (any
recurrence): 60 Gy (9.13) vs. 70 Gy (25.5) p=0.04, but no>70 Gy. LR test was also signiﬁcant for actuarial LCR free survival: 60
Gy (9.13) vs. 66 Gy (22.75) 70 Gy (27.19) or 74 Gy (21.3) (p<0.05) There was not difference in OS across dose level. Patients who
achieved loco-regional control had a non-signiﬁcant better OS 32.17 vs. 26.58 p=0.28.
Conclusions. Patients treated with>60 Gy but no beyond 70 Gy, achieved signiﬁcant better DFS. The leading cause of ﬁrst failure
was IFF, 1 patient developed recurrence outside PTV.
http://dx.doi.org/10.1016/j.rpor.2013.03.764
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Purpose. To evaluate our experience in radical radiochemotherapy (RCT) in lung cancer in term of overall survival and toxicity.
Materials. Between January 2003 and July 2012, 129 eligible patients were recruited (88% male, 12% female, median age 64, with
good performance status). Most patients had scamous cell histology (62%) followed by adenocarcinomas (35%), and giant cells
(3%).The clinical stage was 52% E.IIIA, 40% E.IIIB and 8% E.IV (solitary brain metastasis and one suprarenal metastasis). 77.5%
of patients underwent induction QT based in platinum combined or not with taxano. All patients were treated with conformal
radiotherapy, with a median dose of 66 Gy (180cGy daily), combined with chemotherapy based in cisplatinum. All patients had
V20 less than 33%. 7% received preventive cranial irradiation. (ICP). The primary objective was overall survival (OS); secondary
objectives were progression free survival (PFS), local progression free survival (LPFS) and toxicity. Overall survival was analyzed
with Kaplan–Meier test.
Results. At a median follow-up of 19 months, the median OS was 21 months (95% CI: 17.9–23.7) and median PFS was 16.1 months
(95% CI: 13.3–18.8). LPFS was 20 months (95% CI: 15.8–23.8) and systemic progression free survival was 17.3 (95% CI: 14.5–20).
During the RCT we reported anaemia (48% G1, 15% G2, 6% G3), neutropenia (28% G1, 15% G2, 5% G3, 3% G4), esophagitis (35% G1,
21% G2, 4% G3), dyspnea (17% G1, 5% G2), pneumonitis (2% G1). Induction QT did not improve the OS and PFS. One patient did
not ﬁnished the treatment cause of coronary syndrome. There was one treatment related death, cause of febrile neutropenia.
Conclusions. In our experience radical radiochemotherapy is a feasible treatment option for lung cancer, showing long-term
survival with no inferiority results compared with the published and acceptable toxicities. Induction chemotherapy not modify
the results.
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